Kairos Pharma to Present Initial Phase 1 Data for ENV105 Lung Cancer Treatment at World Conference

Kairos Pharma Ltd. (NYSE American: KAPA) announced its participation in the World Lung Cancer Conference scheduled for September 6–9, 2025, where Principal Investigator Dr. Karen Reckamp will present initial Phase 1 data for ENV105 in non-small cell lung cancer patients. The presentation, titled "Combination of Osimertinib and Carotuximab for Advanced, EGFR-Mutated Non-Small Cell Lung Cancer Patients," focuses on the combination therapy of ENV105 with osimertinib, with the open-label trial's primary objective being to evaluate safety and tolerability of this innovative approach.

The significance of this announcement lies in addressing the critical challenge of drug resistance in cancer treatment, particularly in non-small cell lung cancer where resistance to standard therapies often leads to disease relapse. ENV105 represents a novel approach by targeting CD105, a protein identified as a key driver of resistance to various cancer treatments. According to company information available at https://ibn.fm/KAPA, elevation of CD105 in response to standard therapy results in resistance, and ENV105 aims to reverse this resistance by targeting CD105 to restore the effectiveness of standard therapies across multiple cancer types.

This development matters because non-small cell lung cancer remains one of the most challenging oncology areas with significant unmet medical needs. The presentation at the World Lung Cancer Conference provides the first clinical data on this combination approach, potentially offering new hope for patients who have developed resistance to existing treatments. The implications extend beyond lung cancer, as the CD105 targeting mechanism could be applicable to other cancer types where treatment resistance develops.

The Phase 1 trial data presentation marks an important milestone in the clinical development pathway for ENV105, which is also currently in a Phase 2 clinical trial for castrate-resistant prostate cancer. The dual development approach demonstrates the broad potential application of CD105 targeting across different cancer types. The World Lung Cancer Conference presentation will provide the oncology community with valuable insights into the safety profile and early efficacy signals of this novel combination therapy approach.

For investors and the medical community, this announcement represents progress in Kairos Pharma's pipeline development and underscores the company's focus on utilizing structural biology to overcome drug resistance and immune suppression in cancer. The data presentation at a major international conference adds credibility to the development program and may influence future clinical trial designs and treatment approaches for EGFR-mutated non-small cell lung cancer patients facing treatment resistance challenges.